Evidence map›Paper›PMID 36147210›Full record

ArticleFrontiers in molecular neuroscience2022

Behavioral and Molecular Responses to Exogenous Cannabinoids During Pentylenetetrazol-Induced Convulsions in Male and Female Rats.

Antonella Zirotti Rosenberg, Maxs Méndez-Ruette, Mario Gorziglia, Benjamín Alzerreca, Javiera Cabello, Sofía Kaufmann, Lukas Rambousek, Andrés Iturriaga Jofré, Ursula Wyneken, Carlos A Lafourcade

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Antonella Zirotti RosenbergEscuela de Biotecnología, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.
Maxs Méndez-RuetteCentro de investigación e innovación Biomédica (CiiB), Laboratorio de Neurociencias, Universidad de Los Andes, Santiago, Chile.
Mario GorzigliaFacultad de Medicina, Universidad de Los Andes, Santiago, Chile.
Benjamín AlzerrecaFacultad de Medicina, Universidad de Los Andes, Santiago, Chile.
Javiera CabelloFacultad de Medicina, Universidad de Los Andes, Santiago, Chile.
Sofía KaufmannFacultad de Medicina, Universidad de Los Andes, Santiago, Chile.
Lukas RambousekInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Andrés Iturriaga JofréFacultad de Ciencia, Universidad de Santiago de Chile, Santiago, Chile.
Ursula WynekenFacultad de Medicina, Universidad de Los Andes, Santiago, Chile.
Carlos A LafourcadeDepartment of Biological Sciences, Xi'an Jiaotong-Liverpool University (XJTLU), Suzhou, China.
Universidad de Los Andes, Chile · CLUniversidad de Santiago de Chile · CLUniversidad Mayor · CLUniversity of Zurich · CHXi’an Jiaotong-Liverpool University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is a disabling, chronic brain disease,affecting ~1% of the World's population, characterized by recurrent seizures (sudden, uncontrolled brain activity), which may manifest with motor symptoms (e.g., convulsions) or non-motor symptoms. Temporal lobe epilepsies (TLE) compromising the hippocampus are the most common form of focal epilepsies. Resistance in ~1/3 of epileptic patients to the first line of treatment, i.e., antiepileptic drugs (AEDs), has been an important motivation to seek alternative treatments. Among these, the plant

Indexed as

beta arrestin-2cannabinoidsdentate gyrusepilepsyhippocampusseizures

Identifiers

PMID36147210
PMCPMC9488559
OpenAlexW4290759740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.